Synairgen PLC - respiratory drug discovery and development firm - Reports "positive" data from SNG001 Phase II clinical trial in chronic obstructive pulmonary disease patients with a respiratory viral infection. SNG001 was "well-tolerated" and antiviral responses to viral infections were "significantly enhanced" compared to those receiving placebo.
Current stock price: 194.50 pence
Year-to-date change: up sharply from 5.88p on December 31
By Eric Cunha; firstname.lastname@example.org
Copyright 2020 Alliance News Limited. All Rights Reserved.